F Poordad

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi Review article: thrombocytopenia in chronic liver disease
    F Poordad
    Cedars Sinai Medical Center, Center for Liver Disease and Transplantation, Los Angeles, CA 90048, USA
    Aliment Pharmacol Ther 26:5-11. 2007
  2. ncbi Big changes are coming in hepatitis C
    Fred Poordad
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 13:72-7. 2011
  3. ncbi Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents
    F Poordad
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Viral Hepat 19:449-64. 2012
  4. ncbi Evaluating medical resource utilization and costs associated with thrombocytopenia in chronic liver disease patients
    Fred Poordad
    Liver Disease and Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Med Econ 15:112-24. 2012
  5. ncbi Rapid virologic response: a new milestone in the management of chronic hepatitis C
    Fred Poordad
    Hepatology and Liver Transplantation, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Infect Dis 46:78-84. 2008
  6. ncbi Pathophysiologic basis for the medical management of portal hypertension
    Fred F Poordad
    Cedars Sinai Medical Center, Center for Liver Disease and Transplantation, 8635 W Third Street, Suite 1060W, Los Angeles, CA 90048, USA
    Expert Opin Pharmacother 10:453-67. 2009
  7. ncbi Virological relapse in chronic hepatitis C
    F Fred Poordad
    Gastroenterology and Hepatology, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Antivir Ther 14:303-13. 2009
  8. ncbi Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C
    F F Poordad
    Hepatology and Liver Transplantation, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Aliment Pharmacol Ther 31:1251-67. 2010
  9. ncbi Viral resistance in hepatitis B: prevalence and management
    Fred Poordad
    David Geffen School of Medicine at UCLA, Hepatology and Liver Transplantation, Cedars Sinai Medical Center, Suite 1060, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 12:62-9. 2010
  10. ncbi Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C
    Fred Poordad
    Hepatology and Liver Transplantation, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Hepatology 52:1208-15. 2010

Detail Information

Publications34

  1. ncbi Review article: thrombocytopenia in chronic liver disease
    F Poordad
    Cedars Sinai Medical Center, Center for Liver Disease and Transplantation, Los Angeles, CA 90048, USA
    Aliment Pharmacol Ther 26:5-11. 2007
    ..The liver is the site of thrombopoietin (TPO) synthesis, a hormone that leads to proliferation and differentiation of megakaryocytes and platelet formation. Reduced TPO production further reduces measurable serum platelet counts...
  2. ncbi Big changes are coming in hepatitis C
    Fred Poordad
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 13:72-7. 2011
    ..Along with the first DAAs, other important findings have helped explain long-observed differences between various ethnic groups, as well as new predictive information that can be gleaned from some of the observed adverse events...
  3. ncbi Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents
    F Poordad
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Viral Hepat 19:449-64. 2012
    ..This article will review the key elements of HCV replication and evaluate the various classes of new and investigational DAA that have the potential to create a revolution in the management of patients with chronic hepatitis C...
  4. ncbi Evaluating medical resource utilization and costs associated with thrombocytopenia in chronic liver disease patients
    Fred Poordad
    Liver Disease and Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Med Econ 15:112-24. 2012
    ..This retrospective study estimated the prevalence of thrombocytopenia in a large population of CLD patients and compared medical resource utilization and medical care costs by TCP status...
  5. ncbi Rapid virologic response: a new milestone in the management of chronic hepatitis C
    Fred Poordad
    Hepatology and Liver Transplantation, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Infect Dis 46:78-84. 2008
    ..This assessment is being used to individualize treatment duration, which is currently recommended as 48 weeks in patients infected with HCV genotype 1 (G1) and 24 weeks in those infected with HCV G2 or G3...
  6. ncbi Pathophysiologic basis for the medical management of portal hypertension
    Fred F Poordad
    Cedars Sinai Medical Center, Center for Liver Disease and Transplantation, 8635 W Third Street, Suite 1060W, Los Angeles, CA 90048, USA
    Expert Opin Pharmacother 10:453-67. 2009
    ..Portal hypertension is a potentially life-threatening complication of cirrhosis, resulting from increased intrahepatic resistance and portal inflow...
  7. ncbi Virological relapse in chronic hepatitis C
    F Fred Poordad
    Gastroenterology and Hepatology, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Antivir Ther 14:303-13. 2009
    ....
  8. ncbi Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C
    F F Poordad
    Hepatology and Liver Transplantation, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Aliment Pharmacol Ther 31:1251-67. 2010
    ..For patients with chronic hepatitis C, attaining rapid virological response (RVR) is highly predictive of attaining SVR...
  9. ncbi Viral resistance in hepatitis B: prevalence and management
    Fred Poordad
    David Geffen School of Medicine at UCLA, Hepatology and Liver Transplantation, Cedars Sinai Medical Center, Suite 1060, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 12:62-9. 2010
    ..This article focuses on the common natural variants and those secondary to nucleos(t)ide therapy, as well as diagnostic methods to detect resistance...
  10. ncbi Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C
    Fred Poordad
    Hepatology and Liver Transplantation, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Hepatology 52:1208-15. 2010
    ..These data suggest weight-based dosing with TBV provides a safe and effective treatment alternative to RBV for chronic hepatitis C. American Association for the Study of Liver Diseases...
  11. ncbi Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients
    Fred Poordad
    Cedars Sinai Medical Center Medicine, Los Angeles, CA, USA
    Therap Adv Gastroenterol 2:91-7. 2009
    ..The expected arrival of newer antiviral therapies is still years away, and maximizing the current treatment regimens is of utmost importance to eradicate virus when feasible, while minimizing toxicity...
  12. ncbi Boceprevir for untreated chronic HCV genotype 1 infection
    Fred Poordad
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    N Engl J Med 364:1195-206. 2011
    ..The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies...
  13. ncbi Emerging therapeutic options in hepatitis C virus infection
    Fred Poordad
    Department of Medicine, Cedars Sinai Medical Center, 8635 W Third St, Ste 1060, Los Angeles, CA 90048, USA
    Am J Manag Care 17:S123-30. 2011
    ....
  14. ncbi Interferon free hepatitis C treatment regimens: the beginning of another era
    Fred Poordad
    Hepatology and Liver Transplantation, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 14:74-7. 2012
    ..With the development of new oral direct acting antivirals, interferon free regimens may be available in the next few years. This article discusses some of the preliminary data from interferon free studies...
  15. ncbi Review article: the burden of hepatic encephalopathy
    F F Poordad
    Center for Liver Disease and Transplantation, Cedars Sinai Medical Center and David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Aliment Pharmacol Ther 25:3-9. 2007
    ..Thus, there is need for future studies to more accurately define the burden of hepatic encephalopathy, including minimal hepatic encephalopathy...
  16. ncbi FIBROSpect II: a potential noninvasive test to assess hepatic fibrosis
    F Fred Poordad
    Department of Hepatology and Liver Transplantation, Cedars Sinai Medical Center, 8635 W Third St, 590W, Los Angeles, CA 90048, USA
    Expert Rev Mol Diagn 4:593-7. 2004
    ..FIBROSpect II is an example of a commercially available assay that employs a combination of three markers to distinguish between no, minimal and advanced fibrosis...
  17. ncbi Liver transplant and recurrent disease
    F Fred Poordad
    Hepatology and Liver Transplant Center, University of California, Los Angeles, Cedars Sinai Medical Center 8635 W 3rd Street, Suite 590W, Los Angeles, CA 90048, USA
    Clin Liver Dis 8:461-73. 2004
    ..The use of multiple nucleoside analogs is an intriguing option, based on the HIV experience of reducing drug resistance and optimizing viral suppression, and will likely be further studied...
  18. ncbi De novo non-alcoholic fatty liver disease following orthotopic liver transplantation
    Fred Poordad
    Department of Transplantation, California Pacific Medical Center, San Francisco, USA
    Am J Transplant 3:1413-7. 2003
    ..NAFLD can develop without any of the known predisposing conditions after transplantation, and this raises further questions about the pathogenesis of this condition...
  19. ncbi IDN-6556 Idun Pharmaceuticals Inc
    F Fred Poordad
    Cedars Sinai Medical Center, Liver Transplant Dept, 8635 W Third Street, Suite 590W, Los Angeles, CA 90048, USA
    Curr Opin Investig Drugs 5:1198-204. 2004
    ..In October 2003, a phase II trial of IDN-6556 began in 100 patients undergoing liver transplantation...
  20. ncbi Nonalcoholic fatty liver disease: a review
    F Fred Poordad
    Cedars Sinai Medical Center, 8635 W 3rd Street, 590W, Los Angeles, CA 90048, USA
    Expert Opin Emerg Drugs 10:661-70. 2005
    ..This text reviews the epidemiology of the disease, leading theories of pathogenesis, and treatment options...
  21. ncbi Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Paul Y Kwo
    Department of Medicine, Division of Gastroenterology Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Lancet 376:705-16. 2010
    ..We tested the efficacy of boceprevir, an NS3 hepatitis C virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin...
  22. ncbi Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B
    R G Gish
    Division of Hepatology and Complex GI, Physicians Foundation California Pacific Medical Center, San Francisco, CA 94115 1932, USA
    J Viral Hepat 17:16-22. 2010
    ....
  23. ncbi A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
    I M Jacobson
    Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA
    J Viral Hepat 19:1-26. 2012
    ..This practical guide will serve as a valuable resource for clinicians embarking on the new treatment paradigm of boceprevir or telaprevir in combination with peginterferon/ribavirin for chronic genotype 1 HCV infection...
  24. ncbi Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease
    Stephen A Geller
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Surg Pathol 28:1204-11. 2004
    ..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease...
  25. ncbi Screening for hepatitis B in chemotherapy patients: survey of current oncology practices
    T T Tran
    Department of Medicine, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Aliment Pharmacol Ther 31:240-6. 2010
    ..Current recommendations include screening patients at risk for HBV prior to immunosuppressive therapy and initiating antiviral prophylaxis in patients with chronic HBV...
  26. ncbi Review article: diagnosis and treatment of non-alcoholic fatty liver disease
    M K Oh
    Cedars Sinai Medical Center, Los Angeles, CA, USA
    Aliment Pharmacol Ther 28:503-22. 2008
    ..It is often associated with the metabolic syndrome, although multiple pathogenetic mechanisms have been suggested. In the coming decades, it promises to be the leading cause of liver disease in industrial countries...
  27. ncbi Tobacco and other factors have a negative impact on quality of life in hepatitis C patients
    D Yamini
    Hepatology Section, Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Viral Hepat 18:714-20. 2011
    ..Practitioners should be aware of these associations, particularly tobacco use, which significantly and negatively impacted every variable evaluated...
  28. ncbi Developments in hepatitis C therapy during 2000-2002
    F Fred Poordad
    Department of Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, 8635 W. Third St, 590W, Los Angeles, CA 90048, USA
    Expert Opin Emerg Drugs 8:9-25. 2003
    ..The following chapter is an overview of the patent literature during 2000-mid-2002, and discusses the potential of various treatment modalities for HCV...
  29. ncbi Advances in liver transplantation. New strategies and current care expand access, enhance survival
    Tram T Tran
    University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA
    Postgrad Med 115:73-6, 79-85. 2004
    ..Here, a team of transplant physicians highlights these new strategies, as well as the long-term management issues of special relevance to primary care physicians caring for transplant recipients...
  30. ncbi Imatinib (Gleevec)-induced hepatotoxicity
    Walid S Ayoub
    Center for Liver and Kidney Diseases and Transplantation, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Gastroenterol 39:75-7. 2005
    ..We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib...
  31. ncbi Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C
    Daniel C Malone
    University of Arizona College of Pharmacy, PO Box 210207, Tucson, AZ 85721, USA
    J Manag Care Pharm 11:687-94. 2005
    ....
  32. ncbi Therapeutic strategies in nonalcoholic fatty liver disorders
    F Fred Poordad
    Expert Opin Emerg Drugs 10:237-9. 2005
    ..At present, therapy is aimed at correcting the risk factors, but there are no proven therapies at this point...
  33. ncbi The role of leptin in NAFLD: contender or pretender?
    F Fred Poordad
    J Clin Gastroenterol 38:841-3. 2004
  34. ncbi Hepatitis C infection and the patient with end-stage renal disease
    Fabrizio Fabrizi
    Division of Nephrology and Dialysis, Maggiore Hospital, Policlinico IRCCS, Milan, Italy
    Hepatology 36:3-10. 2002
    ..Interferon remains contraindicated post-RT because of concern about precipitating graft dysfunction...